Citi analyst Joanne Wuensch reiterated a Buy rating on Glaukos (GKOS – Research Report) today and set a price target of $140.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Joanne Wuensch’s rating is based on Glaukos’s strategic positioning and growth potential in the treatment of keratoconus, a progressive eye disorder. The company is poised to benefit from its innovative Epioxa therapy, which represents an advancement in corneal cross-linking (CXL) procedures. This therapy is expected to enhance Glaukos’s market presence and drive revenue growth, particularly with the anticipated commercial launch in 2026 following FDA review.
Glaukos’s first-mover advantage in CXL therapy, demonstrated by its existing iLink procedures, positions it well to capitalize on the under-diagnosed keratoconus market. The potential for increased penetration and market expansion, coupled with the company’s expertise, supports the Buy rating. Additionally, the financial prospects, such as the potential revenue contribution from Epioxa, further justify the positive outlook on Glaukos’s stock.
According to TipRanks, Wuensch is a 5-star analyst with an average return of 7.0% and a 62.73% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Becton Dickinson.
In another report released on June 4, Jefferies also assigned a Buy rating to the stock with a $160.00 price target.